Gilead says HIV prevention injection reduced cases by 96%, sending shares higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
- Oppenheimer sees AI software winners as focus shifts to ROI
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
Goldman Sachs Reiterates Neutral Rating on Gilead Sciences (GILD)
September 12, 2024 10:06 AM EDTGoldman Sachs analyst Salveen Richter reiterated a Neutral rating and $71.00 price target on Gilead Sciences (NASDAQ: GILD).
The analyst comments "GILD reported positive topline interim Ph3 (PURPOSE 2) data where twice-yearly subcutaneous lenacapavir achieved superiority vs. background HIV incidence (bHIV) (primary endpoint) and Truvada (secondary endpoint) in cisgender men, transgender men and women, and gender non-binary... More
Morgan Stanley Reiterates Equalweight Rating on Gilead Sciences (GILD)
September 12, 2024 9:58 AM EDTMorgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $79.00 price target on Gilead Sciences (NASDAQ: GILD).
The analyst comments "GILD announced that in the second Ph3 trial, PURPOSE-2, lenacapavir (twice yearly injectable) reduced HIV infections by 96% and demonstrated superiority to Truvada (daily oral) for HIV prevention in the broader high-risk population (cisgender men, transgender men, transgender women, and gender non-binary individuals; link). There were 2 incident cases of HIV infection among 2,180 participants in the lenacapavir group (99.9% of participants not acquiring HIV infection). GILD is working... More
